
June 24 (Reuters) - Revolution Medicines Inc RVMD.O:
REVOLUTION MEDICINES ENTERS INTO $2 BILLION FLEXIBLE FUNDING AGREEMENT WITH ROYALTY PHARMA TO SUPPORT GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF RAS(ON) INHIBITOR PORTFOLIO FOR PATIENTS WITH RAS-ADDICTED CANCERS
REVOLUTION MEDICINES INC - TERM LOAN INTEREST RATE SOFR PLUS 5.75%, PRINCIPAL DUE BY 2032